Gene Editing and mRNA Companies See Stocks Plummet Despite Pipeline Progress
-
Intellia Therapeutics is developing gene editing therapies that could be game changers for treating certain diseases, and its stock price has dropped over 80% despite progress.
-
Intellia's lead therapies for transthyretin amyloidosis and hereditary angioedema could complete pivotal studies and file for regulatory approval by 2026.
-
Moderna's stock has plunged 80% from its peak due to declining demand for COVID-19 vaccines, but has an RSV vaccine under FDA review and other promising vaccines in the pipeline.
-
Moderna expects to return to sales growth in 2025 and reach breakeven in 2026 as new products come to market.
-
Both stocks remain highly risky and volatile, but aggressive investors willing to wait could see tremendous returns if the companies fulfill their potential.